SCHEMBL6628801

SCHEMBL6628801

c1cncc(C2CN3CCC2CC3)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.66
CYP2A6 P11509 2/20 0.51
KCNH2 Q12809 2/20 0.49
CHRNB2 P17787 4/20 0.49
CHRNA4 P43681 4/20 0.49
ALDH1A1 P00352 2/20 0.47
CHRNB4 P30926 2/20 0.47
CHRNA3 P32297 2/20 0.47
CHRNA2 Q15822 2/20 0.47
LMNA P02545 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
PSIP1 O75475 1/20 0.47
TRPA1 O75762 1/20 0.47
HTR3B O95264 1/20 0.47
CHRNA1 P02708 1/20 0.47
CHRNG P07510 1/20 0.47
MAPT P10636 1/20 0.47
CHRNB1 P11230 1/20 0.47
PTGS1 P23219 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9431069 0.80 CHRNA7 (0.67) CHRNA7
SCHEMBL9458669 0.80 CHRNA7 (0.56) CHRNA7
SCHEMBL3217359 0.80 CHRNA7 (1.00) CHRNA7CHRNB4CHRNA3LMNA
SCHEMBL4785139 0.77 CHRNA7 (0.58) CHRNA7CYP2A6CHRNB2CHRNA4ALDH1A1
SCHEMBL4787167 0.74 CHRNA7 (0.58) CHRNA7CYP2A6CHRNB2CHRNA4ALDH1A1
SCHEMBL9459439 0.72 CHRM2 (0.48) CHRNA7
SCHEMBL9431290 0.72 CHRNA7 (0.44) CHRNA7KCNH2
SCHEMBL5398819 0.72 CHRNA7 (0.53) CHRNA7CYP2A6CHRNB2CHRNA4ALDH1A1
SCHEMBL9677934 0.71 CHRNA7 (0.64) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL9442633 0.71 CHRM2 (0.47) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0412798-A2 Substituted pyridines, their preparation, formulations and use in dementia MERCK SHARP & DOHME LTD. (GB) 1991-02-13 EP claimed
EP-0994875-B1 3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS TARGACEPT INC (US) 2004-03-10 EP disclosed
US-6624173-B1 Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by TARGACEPT, INC. 2003-09-23 US disclosed
US-6525065-B1 Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane TARGACEPT, INC. 2003-02-25 US disclosed
US-5346906-A Enhancement of cholinergic transmitters in treatment of neurological and mental disorders such as Alzheimer's MERCK SHARPE & DOHME LTD. (GB) 1994-09-13 US disclosed
EP-0412798-A2 Substituted pyridines, their preparation, formulations and use in dementia MERCK SHARP & DOHME LTD. (GB) 1991-02-13 EP disclosed